Vicapsys Life Sciences, Inc. is a development stage biotechnology company, which advances proprietary localized immune modulator. Its product name VICAPSYN is the firm's line of proprietary product candidates that is applied to transplantation therapies and related stem-cell applications in the transplantation field. The firm's lead product candidate embodiment in transplantation therapy to treat Type 1 Diabetes is an encapsulated human islet cell cluster that is intended to restore normal glucose control when implanted into the peritoneal cavity of a patient. The company was founded on December 26, 1996 and is headquartered in Suwanee, GA.